Home Blood Count Monitoring for Neutropenia Diagnosis

The Serial Blood Count Study is an important clinical trial evaluating a new way to diagnose and distinguish between two rare blood disorders: cyclic neutropenia (CyN) and severe congenital neutropenia (SCN). This research focuses on testing a home monitoring device called Athelas One, which received FDA clearance for measuring white blood cell (WBC) and absolute neutrophil counts (ANC) from a simple fingerstick blood sample.

For patients with these conditions, getting accurate daily blood counts for 6 weeks is typically difficult. It normally requires repeated trips to a lab for painful arm blood draws. The Athelas device could change this by allowing patients to test themselves at home with just a small finger prick—similar to how people with diabetes check their blood sugar. This approach could make diagnosis easier, less painful, and more convenient.

Why is this research important? These neutropenia conditions involve dangerously low levels of infection-fighting white blood cells. While both are caused by mutations in the same ELANE gene, they have very different risks. SCN carries a 20-25% chance of developing life-threatening leukemia, while CyN has less than 1% risk. This means SCN patients often need stem cell transplants, while CyN patients don't. Current genetic testing can't always tell them apart, but tracking daily neutrophil counts over time can.

The study will enroll about 20 participants aged 5 years and older who have confirmed ELANE mutations. Participants will use the Athelas device daily for 6 weeks. Researchers will check if this home testing method works well and if patients can stick with the routine. The device connects to a smartphone app, letting patients see results and share them with doctors.

This research matters because neutropenia patients often struggle with frequent infections and uncertainty about their condition's severity. Better home monitoring could lead to faster, more accurate diagnoses without the hassle of constant lab visits. For rare diseases like these, every advancement in testing makes a big difference in patients' lives.

Beyond this specific study, research into home blood monitoring represents an exciting shift in healthcare. Devices like Athelas One could transform how we manage many chronic conditions by giving patients more control and reducing burdensome medical appointments. As technology improves, we may see more FDA-cleared home tests that make specialized care accessible to people regardless of where they live. Studies like this help ensure these innovations truly benefit patients while maintaining medical accuracy.